Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cetuximab

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    427 result(s) found for: Cetuximab. Displaying page 9 of 22.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2004-001667-22 Sponsor Protocol Number: EMR62202-002 Start Date*: 2004-10-19
    Sponsor Name:Merck KGaA
    Full Title: Cetuximab (Erbitux) in combination with cisplatin or carboplatin and 5-fluorouracil in the first line treatment of subjects with recurrent and/or metastatic squamous cell carcinoma of the head and ...
    Medical condition: Recurrent and/or metastatic Squamous cell carcinoma of the head and neck (SCCHN)
    Disease: Version SOC Term Classification Code Term Level
    7.0 10025960 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SE (Completed) CZ (Completed) SK (Completed) IT (Completed) ES (Completed) GB (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001288-99 Sponsor Protocol Number: C4221015 Start Date*: 2020-11-26
    Sponsor Name:Pfizer Inc.
    Full Title: AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND C...
    Medical condition: Colorectal cancer (BRAF V600E-mutant mCRC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Ongoing) DE (Ongoing) FR (Not Authorised) BE (Trial now transitioned) SE (Trial now transitioned) IT (Trial now transitioned) PL (Trial now transitioned) SK (Trial now transitioned) BG (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-005547-27 Sponsor Protocol Number: GO28074 Start Date*: 2012-10-24
    Sponsor Name:Genentech, Inc.
    Full Title: A PHASE II, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF FOLFIRI + MEHD7945A VERSUS FOLFIRI + CETUXIMAB IN SECOND LINE IN PATIENTS WITH KRAS WILD-TYPE METASTATIC ...
    Medical condition: Colorectal cancer that does not carry mutation in the KRAS gene
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001167 Adenocarcinoma of colon PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010029 Colorectal cancer NOS LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038019 Rectal adenocarcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) BE (Completed) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004070-26 Sponsor Protocol Number: BRICE Start Date*: 2021-08-02
    Sponsor Name:FONDAZIONE RICERCA TRASLAZIONALE (FORT)
    Full Title: A Phase 1/2 Study Exploring Safety, Tolerability and Efficacy of BRIgatinib in Combination With CEtuximab in Subjects With Advanced EGFR mutated or ALK or ROS1 positive Non-Small Cell Lung Cancer a...
    Medical condition: Advanced or metastatic epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) with acquired resistance to approved EGFR tyrosine kinase inhibitors (TKI); advan...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-005312-41 Sponsor Protocol Number: Panter_2008 Start Date*: 2011-05-02
    Sponsor Name:RWTH Aachen University
    Full Title: Perioperative chemotherapy with FOLFOX plus Cetuximab versus adjuvant FOLFOX plus Cetuximab for patients with resectable liver metastases of colorectal carcinoma
    Medical condition: resectable liver metastases of colorectal carcinoma with proven K-RAS wildtype
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000117-34 Sponsor Protocol Number: Nordic VII Start Date*: 2005-04-22
    Sponsor Name:The Nordic Colorectal Cancer Biomodulation Group
    Full Title: Combination of 5-Fluorouracil/Folinate/Oxaliplatin (Eloxatin®) (FLOX regimen) with Concomitant or Concomitant and Maintenance Administration of Cetuximab (Erbitux®), in First-Line Treatment of Meta...
    Medical condition: Patient with metastatic colorectal cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IS (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-003592-64 Sponsor Protocol Number: UCL/17/0560 Start Date*: 2018-03-16
    Sponsor Name:University College London
    Full Title: A randomised phase II study evaluating the safety and anti-tumour activity of the combination of avelumab and cetuximab relative to avelumab monotherapy in recurrent/metastatic head and neck squamo...
    Medical condition: recurrent/metastatic head and neck squamous cell cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-005540-24 Sponsor Protocol Number: TTCC-2007-01 Start Date*: 2008-03-28
    Sponsor Name:Grupo Español de Tratamiento de los Tumores de Cabeza y Cuello (TTCC)
    Full Title: Ensayo clínico fase III aleatorizado, multicéntrico, de quimioterapia de inducción con la combinación docetaxel, cisplatino y 5-fluorouracilo (TPF) seguido de tratamiento concomitante con Cisplatin...
    Medical condition: Carcinoma escamoso de cabeza y cuello localmente avanzado, no resecable.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007473 Carcinoma squamous LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-012665-61 Sponsor Protocol Number: CC-5013-COLO-001 Start Date*: 2009-11-03
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 2, OPEN-LABEL STUDY TO ASSESS THE EFFICACY AND SAFETY OF LENALIDOMIDE IN COMBINATION WITH CETUXIMAB IN PRETREATED SUBJECTS WITH KRAS MUTANT METASTATIC COLORECTAL CANCER
    Medical condition: Colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) DE (Completed) IT (Completed) FR (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-003900-20 Sponsor Protocol Number: IB 2006-30 Start Date*: 2007-05-14
    Sponsor Name:Institut Bergonié
    Full Title: Essai clinique de Phase II évaluant une chimitohérapie systémique associée au Cetuximab en traitement adjuvant chez des patients complètement résèques par chirurgie de leur carcinose péritonéale is...
    Medical condition: La survenue d'une carcinose péritonéale est un événement gravissime dans l'évolution d'un cancer colorectal. Le travail descriptif de Jayne et col estime la fréquence d'apparition de la carcinose à...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052171 Peritoneal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-006454-30 Sponsor Protocol Number: 23537 Start Date*: 2023-02-09
    Sponsor Name:DIPARTIMENTO DI SCIENZE CHIRURGICHE - UNIVERSITà DEGLI STUDI DI TORINO
    Full Title: Near-infrared molecular imaging for lung cancer detection and treatment during mini-invasive surgery (Phase II Trial)
    Medical condition: To date, lung resection and lymphadenectomy remains the best curative option in patients with early-stage non-small cell lung cancer. Moreover, cancer screening programs have led to a frequent diag...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062042 Lung neoplasm PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062042 Lung neoplasm PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000737-12 Sponsor Protocol Number: CARACAS Start Date*: 2018-07-23
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST
    Full Title: The CARACAS Study. Randomized phase 2 trial of cetuximab and avelumab or avelumab alone for unresectable, locally advanced or metastatic squamous cell anal carcinoma (SCCAC) progressed after at lea...
    Medical condition: Unresectable locally advanced or metastatic squamous anal cancer (SCCAC) progressed after at least one systemic treatment
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10007473 Carcinoma squamous LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005539-22 Sponsor Protocol Number: GO28076 Start Date*: 2012-10-08
    Sponsor Name:Genentech, Inc.
    Full Title: A PHASE II, OPEN-LABEL, RANDOMIZED STUDY OF MEHD7945A VERSUS CETUXIMAB IN PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK WHO HAVE PROGRESSED DURING OR FOLLOWING PLA...
    Medical condition: Head and neck cancer of squamous cell origin
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071536 Head and neck cancer stage IV PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071537 Head and neck cancer stage III PT
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) GB (Completed) ES (Completed) HU (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-000685-36 Sponsor Protocol Number: EMR 200025 – 001 Start Date*: 2006-11-29
    Sponsor Name:Merck KGaA
    Full Title: A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX-4 plus cetuximab versus UFOX plus cetuximab as first-line therapy in subjects with metastatic colorectal cancer
    Medical condition: Metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) FR (Completed) BE (Completed) GR (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-001105-96 Sponsor Protocol Number: EMR62202-046 Start Date*: 2004-09-14
    Sponsor Name:Merck KGaA
    Full Title: Open, randomized, controlled, multicenter phase III study comparing cisplatin / vinoelbine plus cetuximab versus cisplatin / vinorelbine as first-line treament for patients with EGFR-expessing adva...
    Medical condition: Epidermal growth factor receptor-expressing advanced non-small cell lung cancer.
    Disease: Version SOC Term Classification Code Term Level
    7.0 10061873
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) SK (Completed) SE (Completed) AT (Completed) IT (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-006091-38 Sponsor Protocol Number: DeLOSII Start Date*: 2007-05-31
    Sponsor Name:Universität Leipzig
    Full Title: Randomisierte Phase II Screeningstudie zum Einsatz einer TP/TPF-Chemotherapie (Kurzinduktion) vor TP/TPF-Induktion, Radiotherapie mit und ohne Cetuximab in der Primärtherapie des nur durch Laryngek...
    Medical condition: by laryngectomy operable carcinoma of the larynx and the hypopharynx
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023906 Larynx carcinoma LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041849 Squamous cell carcinoma of the hypopharynx LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007097-38 Sponsor Protocol Number: 1200.28 Start Date*: 2009-05-07
    Sponsor Name:SCS Boehringer Ingelheim Comm.V
    Full Title: A randomized, open-label Phase II study of BIBW 2992 versus cetuximab (Erbitux®) in patients with metastatic or recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) after failure of platinum-con...
    Medical condition: Metastatic or recurrent Head and Neck Squamous Cell Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-002105-99 Sponsor Protocol Number: ACT16903 Start Date*: 2022-01-20
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A Phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participa...
    Medical condition: Squamous cell carcinoma of head and neck
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) FR (Completed) NL (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001523-69 Sponsor Protocol Number: V-CHANCE Start Date*: 2014-07-28
    Sponsor Name: Istituto Nazionale Tumori di Napoli - Fondazione "G. Pascale"
    Full Title: Preclinical and clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of head and neck
    Medical condition: Recurrent and/or metastatic squamous cell carcinoma of head and neck
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005013-21 Sponsor Protocol Number: EMR 62202-811 Start Date*: 2009-01-23
    Sponsor Name:Institut de Cancérologie de la Loire
    Full Title: ERBITUX
    Medical condition: Locally advanced non small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025053 Lung cancer non-small cell stage IIIA LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 07:37:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA